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We present a rare ﬁnding of concurrent right testis non-seminomatous mixed germ cell tumor and
muscle invasive urothelial carcinoma of the bladder in a 57-year-old homeless man. The socioeconomic
factors and the disease presentation caused a treatment dilemma in terms of the appropriate type of
neoadjuvant chemotherapy. The patient ultimately underwent upfront surgery with retroperitoneal
lymph node dissection and radical cystoprostatectomy followed by adjuvant cisplatin-based
chemotherapy.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
The estimated incidence of bladder cancer in the year 2014 in US
was much higher in comparison to the incidence of testis cancer
(74,000 vs 8400 cases, respectively).1 To our knowledge, the syn-
chronous occurrence of primary urothelial carcinoma of bladder
(UCB) and testis cancer has not been previously reported. Sepa-
rately, each of these malignancies has well established treatment
algorithms, but the coexisting tumors in the current case presented
an interesting dilemma regarding themost appropriate approach of
therapy and the order in which it should occur.
Case report
A 57-year-old homeless man presented with complaints of
intermittent painless gross hematuria and an enlarging right
testicular mass. His medical history included epididymitis in the
same testicle 7 years earlier, as well as tobacco (30 pack-year),
cocaine and heroin abuse. He denied weight loss or back pain. On
physical exam, he was found to have a hard, non-tender, right
scrotal mass without overlying skin discoloration or erythema.
The scrotal ultrasound demonstrated a large heterogeneous
mass with internal blood ﬂow. A Computed Tomography (CT) of
abdomen/pelvis revealed an enhancing mass measuring 5.1 cm at
the left lateral bladder wall (Fig. 1) and multiple suspicious lymph
nodes (5e10 mm) in the inter-aortocaval and periaortic regions, as
well as a 6.6 cm right testis mass (Fig. 1). Initial laboratory ﬁndingsng, 4160 John R, Suite 1017,
313 745 8222.
ovic).
Inc. This is an open access article uwere normal, except for serum tumormarkers, which revealed both
an elevated alpha-fetoprotein (AFP) (41.2 ng/mL) and lactate
dehydrogenase (LDH) (312 units/L) with normal beta-human cho-
rionic gonadotropin (b-HCG) (<1 mIU/mL).
Initially, the patient underwent a concurrent right radical
orchiectomy and transurethral resection of the bladder tumor. The
morphologic features along with the immunohistochemical
proﬁles were consistent with a mixed germ cell tumor: mature and
immature teratoma (80%), embryonal carcinoma (10%), and yolk sac
tumor (10%). The tumor extended to the tunica albuginea and
epididymis with lymphatic space involvement, pT2 stage (TNM).
His AFP came down to normal levels after 4 weeks (2.4 ng/mL), but
the LDH rose slightly to 320 units/L. In terms of bladder mass,
pathology revealed high grade, muscle invasive urothelial carci-
noma consistent with cT2 stage (TNM).
Treatment options were considered and discussed with the
patient. Initial neoadjuvant chemotherapy with subsequent
cystoprostatectomy may have been appropriate treatment for
the muscle invasive UCB. Given the patient’s history of
non-compliance, as well as the concurrent NSGCT with aggressive
features, prompt surgical treatment was planned with bilateral
template retroperitoneal lymph node dissection (RPLND), radical
cystoprostatectomy, and pelvic lymph node dissection (PLND).
Final pathology after RPLND revealed a total of 44 lymph nodes,
where one left para-aortic and one inter-aortocaval lymph node
were positive for mature teratoma (Fig. 2). Final pathology after
radical cystectomy showed invasive urothelial carcinoma into the
outer half of the muscularis propria of the bladder, negative
resection margins. A total of 21 pelvic lymph nodes were removed,
of which one left external iliac lymph node was positive for
metastatic urothelial carcinoma, with extranodal extension, stage
pT2b, N1 (Fig. 2).nder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. CT demonstrating: a) inter-aortocaval lymph node, b) left lateral bladder wall mass and right testicle mass.
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In terms of testis cancer, our patient was classiﬁed as
good risk, CS IIA NSGCT (American Joint Committee on
Cancer).2 However, CT ﬁnding of suspicious retroperitoneal nodes
(5e10 mm) as well as presence of lymphovascular invasion and
embryonal component in the primary testis tumor placed our
patient at higher risk for occult metastasis.3,4 It has been reported
that the rate of metastasis when both entities are present varies
from 30 to 90%, and in the absence of the two, the risk of metastasis
is<20%.4 Embryonal carcinoma has been considered to be the most
undifferentiated cell type of NSGCT, with totipotential ability to
become other NSGCTs, including teratoma at primary or metastaticFigure 2. Pathology slide of metastatic RPLN showing a) teratoma (hematoxylin and eosin
teratoma tissue; c) metastatic urothelial carcinoma in pelvic lymph node (hematoxylin andsites. The deﬁnition of embryonal predominance in higher risk
patients varies in literature between 45 and 90%.4 In our patient, it
was reported at 10% but its presence may still portend to its
metastatic potential. A majority (80%) of our patient’s primary testis
tumor was noted to be teratoma, which is a chemo- and radio-
resistant tumor only amenable to cure by surgical excision, which
further inﬂuenced our treatment decision-making.
The established initial treatment options for Stage IIA NSGCT
include either induction chemotherapy with Etoposide-Cisplatin
(EP) 4 or Bleomycin-Etoposide-Cisplatin (BEP) 3, or primary
RPLND. Any one of these approaches results in survival rates
exceeding 95%, especially with the advent of cisplatin-based
combination chemotherapy.4 Previously reported high 5-yearstain), and b) Glial Fibrillary Acidic Protein (GFAP) stain consistent with glial origin of
eosin stain).
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stage N1 after RPLND alone, however, supported a surgical
approach over primary chemotherapy.4 This approach allows a
large portion of patients to avoid systemic chemotherapy and its
well described long-term side effects. In addition, in considering
the patient’s mixed germ cell tumor with potential teratoma
elements at metastatic sites, complete cure would require surgery
to remove the teratomatous components. For our homeless patient,
compliance with upfront chemotherapy and follow-up posed a
signiﬁcant problem. Furthermore, the coexistence of his bladder
and testicular malignancies presented a challenge in the selection
of an appropriate chemotherapy regimen.
Current level 1 evidence for treatment of MI-UCB demonstrates
a survival advantage in patients receiving neoadjuvant chemo-
therapy with methotrexate, vinblastine, doxorubicin and cisplatin
(MVAC), or gemcitabine and cisplatin (GC), followed by radical
cystectomy.5 The role of adjuvant chemotherapy remains uncertain
due to lack of prospective randomized trials, but some meta-
analyses reports have shown a beneﬁt in patient overall and
disease-free survivals. After a discussion with the patient and a
multidisciplinary team at our institution, initial surgical interven-
tion including a combined bilateral template RPLND with radical
cystoprostatectomy and PLND was performed. With the ﬁnding of
teratoma in his nodes, RPLND allowed our patient to be potentially
cured. Clearly, the beneﬁt of initial surgical approach also providedmore deﬁnitive staging and guidance for further chemotherapy.
Metastatic UCB unfortunately does not share the same success with
testis cancer. As a result, our ﬁnal recommendation for our patient
with coexisting metastatic urothelial and testis cancers favors early
adjuvant MVAC chemotherapy and observation (conservative
imaging and tumor markers) without adjuvant chemotherapy,
respectively.Conﬂicts of interest
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